Molecular Diagnostics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… of Shionogi) FEI Company Foundation Medicine Fujirebio Diagnostics GE Healthcare Genetic Technologies Geneva Bioinformatics (GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

SALT LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass …

Follow Molecular Diagnostics:    

Biochips Technologies, Companies, Applications & Markets Report 2019 - Market Size in 2018 and Projected Value for the Years 2023 and 2028 | PR Newswire | 12/4/2019

… Chip for protein identification 2D displacement chromatography using HPLC Chip LabChip for protein analysis MALDI-MS imaging and protein microarrays Multiplexed Protein Profiling on Microarrays Peptide microarrays ProteinChip Protein chips for antigen-antibody interactions molecular diagnostics Proteomic pattern analysis Reverse phase protein microarrays Single molecule array TRINECTIN proteome chip New developments in protein chips/microarrays Microfluidic devices for proteomics-based diagnostics Viral protein chip Use of microarray technologies in human …

Global Cytogenetics Technologies, Companies & Markets, 2018-2023 & 2028 | PR Newswire | 12/4/2019

… is QD (quantum dot)-FISH probes, which can detect down to the single-molecule level. There are connections between cytogenetics and biomarkers of genetic disorders as well as cancer. Biomarkers are very important for molecular diagnostics . Not only are molecular diagnostic technologies used for the discovery of biomarkers, biomarkers are the basis of several diagnostics. As a means to understand pathomechanism of disease and as links between diagnostics and therapeutics …

Zacks: Analysts Expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Will Post Earnings of -$0.11 Per Share | 12/4/2019

Wall Street brokerages predict that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will report earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks . Two analysts have provided estimates for HTG Molecular Diagnostics’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.08). HTG Molecular Diagnostics reported earnings per share of ($0.07) during the same quarter last year, which …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

… Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends such as: personalized medicine pharmacogenomics liquid biopsy emergence …

Global STD Diagnostics Markets to 2024 - Implementation of National Screening Programs Spur Industry Growth | Benzinga | 12/4/2019

STD Diagnostics Market - Growth, Trends, major shift from conventional technologies to molecular diagnostics for the diagnosis of STD’s is the major breakthrough for the growth of the market. Additionally, the growing prevalence of STD’s globally increases patient awareness through education campaigns and growing government initiatives are anticipated to drive market growth. According to UNAIDS in 2018, there were 37.9 million [32.7 million-44.0 million] people living with HIV. Furthermore, the …

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits - December 4, 2019 - Zacks.com | 12/4/2019

Illumina, Inc. ( ILMN - Free Report ) recently inked a non-exclusive partnership deal with ArcherDX, Inc., a growth-stage molecular diagnostics company. Both companies aim at developing in-vitro diagnostic (IVD) tests for ArcherDX’s portfolio of next-generation sequencing (NGS)-based companion diagnostics. However, financial terms of the deal have been kept under wraps. Deal in Detail Per the agreement, ArcherDX will develop IVD tests that will be performed on Illumina’s …

Global Biomarkers Companies, Technologies, Markets 2018-2028: Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics | PR Newswire | 12/4/2019

… as well as the development has increased remarkably since the beginning of the 21st century. This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker. Currently, the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in …

Global Hematologic Malignancies Testing Market 2019-2025: Increasing Adoption of Inorganic Growth Strategies in the Market | PR Newswire | 12/4/2019

… the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. The massive scope in the emerging economies and technological advancements in the field of molecular diagnostics are also expected to provide growth opportunities for players in the market. The molecular discovery of disease-causing genes in blood cancers has led to the global phenomenon known as precision diagnostics in hematologic …

Global STD Diagnostics Markets to 2024 – Implementation of National Screening Programs Spur Industry Growth | 12/4/2019

Dublin, The “STD Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The major shift from conventional technologies to molecular diagnostics for the diagnosis of STD’s is the major breakthrough for the growth of the market. Additionally, the growing prevalence of STD’s globally increases patient awareness through education campaigns and growing government initiatives are anticipated to drive market growth. According to UNAIDS in 2018 …

Cerus (NASDAQ:CERS) vs. Viatar CTC Solutions (NASDAQ:VRTT) Head-To-Head Analysis | 12/4/2019

… Summary Cerus beats Viatar CTC Solutions on 6 of the 9 factors compared between the two stocks. About Viatar CTC Solutions Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used …

-$0.11 Earnings Per Share Expected for HTG Molecular Diagnostics Inc (NASDAQ:HTGM) This Quarter - Ticker Report | 12/4/2019

Brokerages expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to post earnings per share of ($0.11) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for HTG Molecular Diagnostics’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.13). HTG Molecular Diagnostics posted earnings per share of ($0.07) during the same quarter last year, which indicates a negative year-over-year growth rate of 57.1 …

Ranoli facility to manufacture American created IVDs | 12/4/2019

… obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (IVDs) from their facility in Ranoli. The joint venture CoSara Diagnostics Pvt Ltd has received the clearance, said the molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests. The Saragene™ tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) meet the requirements of the Central …

Myriads Prequel Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Financial Buzz | 12/4/2019

SALT LAKE CITY, Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass index (BMI). The Prequel Prenatal …

Myriad Genetics (NASDAQ:MYGN) Shares Stop Bleeding on Positive Study of Prenatal Genetics Test | 12/4/2019

December 4, 2019 It’s certainly been a white-knuckle ride in 2019 for shareholders of the molecular diagnostics and precision medicines company Myriad Genetics (NASDAQ: MYGN), with shares doubling and getting halved over a few weeks this summer. A slow climb starting in June from $22 culminated with a 55% explosion on August 1-2 to $48 thanks to news that UnitedHealthcare (NYSE: UNH) was starting to cover a MYGN genetics …

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays | Business Wire | 12/3/2019

SALT LAKE CITY- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), their joint venture for manufacturing, has obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (“IVDs”) from their facility in Ranoli, India. The Saragene™ tests for Mycobacterium …

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Globe Newswire | 12/3/2019

… diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products …

Pharmacogenomics Technology Market To Witness Swift Growth Based On Rising Awareness Regarding Personalized Therapy Among Patients Till 2025 | Million Insights | Markets Insider | Business Insider | 12/3/2019

… and cancer, increase in awareness amongst the patients regarding personalized therapy, and adoption of pharmacogenomics by loads of healthcare professionals. The pharmacogenomics technology market is also likely to get bolstered technological advancements related to molecular diagnostics . At the same time, there is a dearth on the part of highly skilled and trained healthcare professionals in conducting pharmacogenomics diagnostics tests. Besides, emerging economies need to think twice before affirming pharmacogenomics tests …

Global IVD Test Procedure Volumes 2019-2024: Opportunity for New Entrants with Diagnostic Products, and Existing Product Marketers | PR Newswire | 12/3/2019

… routine patient check-ups, and the pre-admission and pre-discharge testing of hospital patients are predicted to boost the total global volume of laboratory clinical chemistry procedures. Molecular Testing Procedures The science of molecular diagnostics compares DNA, RNA, genes, or proteins found in extracted human specimens to reference probes containing genetic matter linked to specific diseases, disorders or other medical conditions. Molecular assays continue to penetrate new and existing …

Diagnostic Tests

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Precision Medicine

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

SALT LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass …

Medical Research

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co. Merck KGaA Metabolon Michael J Fox Foundation Myriad Genetics …

Zacks: Analysts Expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Will Post Earnings of -$0.11 Per Share | 12/4/2019

Wall Street brokerages predict that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will report earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks . Two analysts have provided estimates for HTG Molecular … issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. HTG Molecular Diagnostics had a …

Genomics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Biomarkers • Efficacy Biomarkers • Validation Biomarkers • This report also breaks down the revenue forecast for the global biomarkers market by Discipline: • Genomics • Proteomics • Bioinformatics • Other • This report also breaks down the revenue forecast for the global … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Biochips Technologies, Companies, Applications & Markets Report 2019 - Market Size in 2018 and Projected Value for the Years 2023 and 2028 | PR Newswire | 12/4/2019

… MALDI-MS imaging and protein microarrays Multiplexed Protein Profiling on Microarrays Peptide microarrays ProteinChip Protein chips for antigen-antibody interactions molecular diagnostics Proteomic pattern analysis Reverse phase protein microarrays Single molecule array TRINECTIN proteome chip … cancer cells 6. Biochips & Microarrays for Epigenetics Introduction Epigenomic technologies Epigenomics Digital Phenotype Global methylation analysis Illumina’s assays for analysis of methylation sites GenomicTree’s MDScan technology Orion’s MethylScope technology ChIP-chip Microarray for immunogenetic testing …

Biotech

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… 2014-2019: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Most of the deals included within the report occur when a … HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive Surgical INVO Bioscience Irvine Scientific IsoRay ITEM Medical Technologies IviGen …

Companion Diagnostics

Does This Provide a Reason to Sell Myriad Genetics, Inc. (MYGN)? The Stock Has Formed Multiple Bottom Pattern | Finance Recorder | 12/4/2019

Investors sentiment increased to 1.08 in 2019 Q2. Its up 0.03, from 1.05 in 2019Q1. It increased, as 29 investors sold Myriad Genetics, Inc. shares while 61 reduced holdings. 22 funds opened positions while 75 raised stakes. 77.57 million shares or 1.24% more from 76.62 million shares in 2019Q1 were reported. 133,135 are owned by Ny State Common Retirement Fund. Taylor Frigon Ltd Liability reported 45,903 shares or 0.9% of …

Biochips Technologies, Companies, Applications & Markets Report 2019 - Market Size in 2018 and Projected Value for the Years 2023 and 2028 | PR Newswire | 12/4/2019

… for protein identification 2D displacement chromatography using HPLC Chip LabChip for protein analysis MALDI-MS imaging and protein microarrays Multiplexed Protein Profiling on Microarrays Peptide microarrays ProteinChip Protein chips for antigen-antibody interactions molecular diagnostics Proteomic pattern analysis Reverse phase protein microarrays Single molecule array TRINECTIN proteome chip New developments in protein chips/microarrays Microfluidic devices for proteomics-based diagnostics Viral protein chip Use of microarray technologies in human protein …

Medicare

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm …

Food and Drug Administration

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency) ETH Zurich European Commission European Federation of Pharmaceutical …

Global STD Diagnostics Markets to 2024 - Implementation of National Screening Programs Spur Industry Growth | Benzinga | 12/4/2019

STD Diagnostics Market - Growth, Trends, major shift from conventional technologies to molecular diagnostics for the diagnosis of STD’s is the major breakthrough for the growth of the market. Additionally, the growing prevalence of STD’s globally … sexually transmitted diseases diagnostics industry. In May 2019, the US Food and Drug Administration (FDA) has cleared two tests “The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)” to detect Chlamydia …

Clinical Research

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong Kong University of Michigan University of Oxford University of Siena Upsher-Smith …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong Kong University of Michigan University of Oxford University of Siena Upsher-Smith …

Rapid Diagnostics

Global STD Diagnostics Markets to 2024 - Implementation of National Screening Programs Spur Industry Growth | Benzinga | 12/4/2019

STD Diagnostics Market - Growth, Trends, major shift from conventional technologies to molecular diagnostics for the diagnosis of STD’s is the major breakthrough for the growth of the market. Additionally, the growing prevalence of STD’s globally increases patient awareness through education campaigns and growing government initiatives are anticipated to drive market growth. According to UNAIDS in 2018, there were 37.9 million [32.7 million-44.0 million] people living with HIV. Furthermore, the …

Sepsis Diagnostics - Global Markets by Assay Technology, 2024 | PR Newswire | 11/26/2019

… Sepsis Diagnostics 1.1.1 Sepsis the medical emergency 1.1.2 Sepsis Diagnosis and Comorbidity 1.3 Market Definition 1.3.1 Market Size 1.3.2 Currency 1.3.3 Years 1.3.4 Microbiology 1.3.5 Other Infectious Disease 1.3.6 Syndromic PoC 1.3.7 Biomarkers Molecular Diagnostics 1.3.8 Biomarkers Other 1.3.9 Limitations 1.4 Methodology 1.5 U.S. Medical Market and laboratory Testing - Perspective 1.4.1 U.S. Medicare Expenditures for Laboratory Testing 2. Sepsis - Current Science 2.1 What is Sepsis? 2.1.1 Organ Damage 2.1.2 Neonatal …

Siemens

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) – The “Molecular Diagnostics for Cancer - Markets, Strategies & Trends, Forecasts By Cancer Type & By Country - With Executive and Consultant Guides - 2020 To 2024” report has been added to ResearchAndMarkets.com’s offering … Pfizer Promega Protagen Diagnostics Qiagen Quanterix Rarecells SAS Roche Diagnostics Siemens Silicon Biosystems SkylineDx SRI International Sysmex Thermo Fisher Trovagene Vortex Biosciences 6. The Global Market for MDx Cancer 6.1 MDx Cancer - Global Market Overview …

Qiagen

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Hematologic Malignancies Testing Market to 2025: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… Genetic Testing for Cancers 2.3 Market Opportunities 2.3.1 Opportunities in the Emerging Economies 2.3.2 Technological Advancements in the Field of Molecular Diagnostics 3 Competitive Landscape 3.1 Key Strategies and Developments 3.2 Product Scenario 3.3 Funding … Rad Laboratories, Inc. Sysmex Corporation ASURAGEN, INC. Cancer Genetics Inc. QIAGEN N.V. ArcherDX, Inc. Adaptive Biotechnologies ICON plc Quest Diagnostics Incorporated ARUP Laboratories Invivoscribe, Inc. NeoGenomics Laboratories, Inc. For more information about this report visit …

Thermo Fisher

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Thermo Fisher Scientific

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Guardant Health

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) – The “Molecular Diagnostics for Cancer - Markets, Strategies & Trends, Forecasts By Cancer Type & By Country - With Executive and Consultant Guides - 2020 To 2024” report has been added to ResearchAndMarkets.com’s offering … Cancer CDx Deal With Bristol-Myers Squibb Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling Business Illumina to Launch New …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Benzinga | 12/4/2019

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) – The “Molecular Diagnostics for Cancer - Markets, Strategies & Trends, Forecasts By Cancer Type & By Country - With Executive and Consultant Guides - 2020 To 2024” report has been added to ResearchAndMarkets.com’s offering … Cancer CDx Deal With Bristol-Myers Squibb Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling Business Illumina to Launch New …

Abbott Laboratories

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Hematologic Malignancies Testing Market to 2025: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… Genetic Testing for Cancers 2.3 Market Opportunities 2.3.1 Opportunities in the Emerging Economies 2.3.2 Technological Advancements in the Field of Molecular Diagnostics 3 Competitive Landscape 3.1 Key Strategies and Developments 3.2 Product Scenario 3.3 Funding … Global Hematologic Malignancies Testing Market (by Region) 10 Company Profiles Abbott Laboratories Illumina, Inc. F. Hoffmann-La Roche Ltd Bio-Rad Laboratories, Inc. Sysmex Corporation ASURAGEN, INC. Cancer Genetics Inc. QIAGEN N.V. ArcherDX, Inc. Adaptive …

GeneSight

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Merck

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical Hammock Pharmaceuticals HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive … MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic …

EndoPredict

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … myChoice CDx, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United …

Does This Provide a Reason to Sell Myriad Genetics, Inc. (MYGN)? The Stock Has Formed Multiple Bottom Pattern | Finance Recorder | 12/4/2019

… DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our …

Genomic Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… biomarker technology providers and biomarker diagnostic developers : • AB SCIEX • Agilent • Axela Inc • Caprion Proteomics • Charles River Laboratories • Critical Diagnostics • Epigenomics • Genomic Health • ICON plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Molecular Diagnostics for Cancer - Worldwide Markets, Strategies & Trends, Forecasts by Cancer Type & Country (2020-2024) | Globe Newswire | 12/4/2019

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) – The “Molecular Diagnostics for Cancer - Markets, Strategies & Trends, Forecasts By Cancer Type & By Country - With Executive and Consultant Guides - 2020 To 2024” report has been added to ResearchAndMarkets.com’s offering … Sciences Exosome Diagnostics Fluidigm Corp Fluxion Biosciences Foundation Medicine Freenome Genomic Health GenomOncology GRAIL Guardant Health HalioDx Horizon Discovery HTG Molecular Diagnostics iCellate Illumina Incell Dx Inivata Integrated Diagnostics Invivoscribe Leica Biosystems Luminex MDx Health …

William Blair

Andra AP fonden Boosts Stock Position in EXACT Sciences Co. (NASDAQ:EXAS) - American Banking News | 12/4/2019

… rating and set a $135.00 target price on shares of EXACT Sciences in a research note on Thursday, October 31st. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on … by insiders. EXACT Sciences Company Profile Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a …

Pictet Asset Management Ltd. Boosts Stock Position in Guardant Health Inc (NASDAQ:GH) | 12/3/2019

… Tuesday, November 12th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating …

SVB Leerink

Q2 2020 EPS Estimates for Myriad Genetics, Inc. (NASDAQ:MYGN) Cut by Svb Leerink | 11/23/2019

Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities researchers at Svb Leerink dropped their Q2 2020 EPS estimates for shares of Myriad Genetics in a note issued to investors on Tuesday, November 5th, according to Zacks Investment Research . Svb Leerink analyst P. Souda now forecasts that the company will post earnings of $0.23 per share for the quarter, down from their previous estimate of $0.38. Svb Leerink also issued estimates for Myriad …

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to Post FY2019 Earnings of ($0.63) Per Share, Svb Leerink Forecasts | 11/17/2019

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) – Stock analysts at Svb Leerink lifted their FY2019 EPS estimates for HTG Molecular Diagnostics in a report released on Wednesday, November 13th. Svb Leerink analyst P. Souda now forecasts that the medical research company will post earnings per share of ($0.63) for the year, up from their previous estimate of ($0.71). Svb Leerink also issued estimates for HTG Molecular Diagnostics’ Q4 2019 earnings at …

Zacks Equity Research

Abbott (ABT) Up 2.1% Since Last Earnings Report: Can It Continue? | Zacks | 11/15/2019

You follow Realtime BLOG - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article A month has gone by since the last earnings … by solid growth in the United States and international markets. Molecular Diagnostics slipped 6.4%, on an organic basis. Point of Care Diagnostics sales were up 6.7% on an organic basis led by the company’s i …

GenMark Diagnostics (GNMK) Reports Q3 Loss, Tops Revenue Estimates | Zacks | 11/7/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article GenMark Diagnostics ( GNMK - Free Report ) came out … of -5.26%. A quarter ago, it was expected that this molecular diagnostics company would post a loss of $0.21 per share when it actually produced a loss of $0.23, delivering a surprise of -9.52%. Over …

Merrill Lynch

Qiagen stock price target raised to $40 from $25 at J.P. Morgan | MarketWatch | 11/14/2019

… movers Oct. 8, 2019 at 12:40 p.m. ET on Seeking Alpha In a report released today, Derik De Bruin from Merrill Lynch maintained a Hold rating on Qiagen NV (QGEN), with a price target …[…] Oct … transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is …

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q4 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Financial Officer Conference Call Participants Tycho Peterson - JPMorgan Bill Quirk - Piper Jaffray Jack Meehan - Barclays Ivy Ma - Bank of America Merrill Lynch Chris Lin - Cowen Mason Austen - Morgan Stanley Anthony Petrone - Jefferies Andrew Brackmann - William … very good results in our largest businesses, Breast Health and Molecular Diagnostics, we were excited by the continued strengthening of Surgical, which posted its best growth in 10 quarters. Before we discuss the quarterly details …

Khosla Ventures

Inflammatix Announces Funding from BARDA to Advance HostDx™ Tests | PR Newswire | 11/14/2019

… News provided by Nov 14, 2019, 07:00 ET Share this article BURLINGAME, Calif. , Nov. 14, 2019 /PRNewswire/ – Inflammatix , a pioneering molecular diagnostics company, announced today an agreement with the Biomedical Advanced Research and Development Authority … of care. The Burlingame, Calif. -based company is funded by Khosla Ventures, Northpond Ventures, the Stanford-StartX Fund and Think.Health Ventures. For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc …

Two Pore Guys Rebranded as Ontera Under New Leadership to Bring NextGeneration Molecular Diagnostics to the Field and Point of Use - Scientific Technology News | 5/10/2019

… Executive Officer and Andrea Chow, Ph.D., as Senior Vice President of Engineering. The company also announced that its lead investor, Khosla Ventures, has exercised its final warrant. Ontera’s primary focus is on supporting sustainable agriculture … nanopore chip-based sensors. These platforms will bring next-generation molecular diagnostics closer to the point of need, anywhere on earth. For more information, visit www.ontera.bio. Media Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 [email protected]

Cambridge Innovation Capital

Sense Biodetection Raises £12.3m to Progress Instrument-Free Molecular Diagnostics | BioSpace | 10/30/2019

Sense Biodetection Raises £12.3m to Progress Instrument-Free Molecular Diagnostics Published: Oct 29, 2019 Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, True Point-of-Care ™ products 29 October 2019 … company has raised £10.5m Series A investment co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management. Concurrent with the investment, Sense has also …

Earlybird Co-leads Investment In Instrument-free Molecular Diagnostics Company Sense Biodetection | BioSpace | 10/30/2019

Earlybird Co-leads Investment In Instrument-free Molecular Diagnostics Company Sense Biodetection Published: Oct 29, 2019 Sense Biodetection Limited raises £12.3m to progress instrument-free molecular diagnostics The investment is co-led by Earlybird and Cambridge Innovation Capital (CIC), with participation from Jonathan Milner, and Mercia Asset Management Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, true point-of-care products Cambridge, UK, 29th October …

BlackRock Inc.

HTG Molecular Diagnostics (NASDAQ:HTGM) Rating Reiterated by Cantor Fitzgerald | 10/29/2019

HTG Molecular Diagnostics (NASDAQ:HTGM) Rating Reiterated by Cantor Fitzgerald Posted by Amber Abramson on Oct 29th, 2019 Tweet HTG Molecular Diagnostics (NASDAQ:HTGM) ‘s stock had its “overweight” rating reiterated by research analysts at … after buying an additional 242,497 shares during the last quarter. BlackRock Inc. lifted its position in HTG Molecular Diagnostics by 504.3% in the 2nd quarter. BlackRock Inc. now owns 405,837 shares of the medical research …

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Receives $2.83 Consensus Target Price from Analysts | 10/28/2019

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell … after buying an additional 1,760,533 shares during the last quarter. BlackRock Inc. raised its holdings in shares of HTG Molecular Diagnostics by 504.3% during the second quarter. BlackRock Inc. now owns 405,837 shares of the …

Mayo Clinic

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co. Merck KGaA Metabolon Michael J Fox Foundation Myriad Genetics …

AACC India Section’s CME on clinical chemistry and immunoassay held in Mumbai | 12/3/2019

… Ramanathan, Chief Clinical Chemistry Service, Memorial Sloan- Kethering Cancer Center, New York; Dr Ravender Singh, Co-Director of Endocrine Laboratory, Mayo Clinic, Rochester, MN; Dr Arnab Pal, Additional Professor, Biochemistry, PGI, Chandigarh; Dr Robert Rej … objective is to connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, laboratory management and other frontier areas of laboratory medicine …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive Surgical INVO Bioscience Irvine Scientific IsoRay ITEM Medical Technologies IviGen Janssen Pharmaceuticals Johns Hopkins University Joylux Karolinska Institute Kissei Pharmaceutical Kite Pharma Knight Therapeutics Kyoto University Laboratory Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda …

Jefferson Health

Using Artificial Intelligence to Predict Risk of Thyroid Cancer on Ultrasound | 11/6/2019

… do with a nodule when the risk of cancer is uncertain. A new study from the Sidney Kimmel Cancer Center – Jefferson Health investigates whether a non-invasive method of ultrasound imaging, combined with a Google … biopsy proves inconclusive, the sample can be further tested via molecular diagnostics to determine risk of malignancy. These tests look for the presence of certain mutations or molecular markers that are associated with malignant thyroid …

Using AI to predict risk of thyroid cancer on ultrasound | 10/29/2019

… do with a nodule when the risk of cancer is uncertain. A new study from The Sidney Kimmel Cancer Center - Jefferson Health investigates whether a non-invasive method of ultrasound imaging, combined with a Google … biopsy proves inconclusive, the sample can be further tested via molecular diagnostics to determine risk of malignancy. These tests look for the presence of certain mutations or molecular markers that are associated with malignant thyroid …

UPMC

HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29 - GuruFocus.com | 10/22/2019

… Molecular Diagnostics, Inc. ( HTGM) , a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29 th in New York City. The event will feature a presentation by Adam Brufsky, M.D., Ph.D., Co-Director, Comprehensive Breast Cancer Center and Medical Director, Woman’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh PA …

HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29 | BioSpace | 10/22/2019

HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29 TUCSON, Ariz., Oct. 22, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) , a diagnostic company whose mission … Cancer Center and Medical Director, Woman’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh PA, who will discuss the current challenges in diagnosing breast cancer and unmet medical needs and optimizing treatment. Dr. Brufsky …

HCA

Two Pore Guys Rebranded as Ontera Under New Leadership to Bring Next-Generation Molecular Diagnostics to the Field and Point of Use | Business & Finance | heraldchronicle.com | Business Wire | 5/9/2019

Spring Has Sprung Photo AP Two Pore Guys Rebranded as Ontera Under New Leadership to Bring Next-Generation Molecular Diagnostics to the Field and Point of Use 6 hrs ago Save SANTA CRUZ, Calif.–(BUSINESS … Prior to that, she was Executive in Residence for GE Healthcare Ventures, and General Manager at McKesson for seven years during which she oversaw multi-billion dollar P&L. Ms. Thinard-McLane serves on the …

Global Molecular Diagnostics Market Forecasts to 2025 - Research and Markets | Business Wire | 12/12/2017

DUBLIN- The “Global Molecular Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025” report has been added to Research and Markets’ offering. The global … Corporation F.Hoffman La-Roche Ltd. Novartis AG Qiagen N.V. Siemens Healthcare Sysmex Corporat For more information about this report visit https://www.researchandmarkets.com/research/q4czlh/global_molecular?w=4 Contacts Research and Markets Laura Wood, Senior …

Melinda Gates

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL&H Bluebird Bio BMV Medica Boston Scientific … HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive Surgical INVO Bioscience Irvine Scientific IsoRay ITEM Medical Technologies IviGen …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL&H Bluebird Bio BMV Medica Boston Scientific … HealthNet Helix Helix BioPharma Hologic Hookipa Biotech Hope Medicine HTG Molecular Diagnostics Igantia Therapeutics iGenomix Illumina Imaxio IncellDx InnerOptic Technology Innovus Pharmaceuticals Inovio Pharmaceuticals Intuitive Surgical INVO Bioscience Irvine Scientific IsoRay ITEM Medical Technologies IviGen …

Dwight Egan

Ranoli facility to manufacture American created IVDs | 12/4/2019

… diagnostics (IVDs) from their facility in Ranoli. The joint venture CoSara Diagnostics Pvt Ltd has received the clearance, said the molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests … a multiplexed panel specifically for blood-bank screening. Company CEO Dwight Egan remarked “India is soon to become the largest healthcare market on the planet and the best place for Co-Primer-powered products to …

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays | Business Wire | 12/3/2019

SALT LAKE CITY- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or … more, including a multiplexed panel specifically for blood-bank screening. Dwight Egan, Company CEO, remarked, “India is soon to become the largest healthcare market on the planet and the best place for CoPrimer-powered products …

Sara Peerun

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-biomarkers … Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson …

Visiongain Report Offers Transformative Insights on the $97bn Precision Medicine Market | Markets Insider | Business Insider | 8/6/2019

Global Precision Medicine Market Forecast 2019-2029 LONDON , Aug. 6, 2019 /PRNewswire/ – Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular … act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-precision-medicine-market-forecast-2019-2029/ download_sampe_div Report Scope • Global …

Michael Nall

Biocept’s Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium® | PR Newswire | 12/3/2019

… Selector™ assays to help physicians better understand treatment options for their patients with breast cancer,” said Biocept’s President and CEO Michael Nall . “Our liquid biopsy platform provides the unique ability to utilize our proprietary CTC … interest in breast cancer. About Biocept Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to …

David Clair

Bio-Techne To Present At The Evercore ISI 2nd Annual HealthCONx Conference | PR Newswire | 11/25/2019

… molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide. Contact: David Clair, Senior Director, Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation Related Links …

Bio-Techne To Present At The Evercore ISI 2nd Annual HealthCONx Conference - GuruFocus.com | 11/25/2019

… molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide. Contact: David Clair, Senior Director, Corporate Development [email protected] 612-656-4416 View original content to download multimedia: http …

Thierry Bernard

Why many bidders fight for Qiagen | 11/19/2019

… the NGS area his resignation. Instead of Schatz, who was always seen as an advocate of the independence of Qiagen, Thierry Bernard took over as interim CEO, the leadership of the group. In response to … he also supplies research laboratories and is heavily involved in molecular diagnostics. It would also be problematic for Roche to continue Qiagen’s activities in the development of companion diagnostics for other pharmaceutical companies. Pure diagnostics …

Qiagen stock price target raised to $40 from $25 at J.P. Morgan | MarketWatch | 11/14/2019

… 2019 Q3 - Results - Earnings Call Presentation Nov. 5, 2019 at 2:28 p.m. ET on Seeking Alpha QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q3 2019 Results - Earnings Call Transcript Oct. 31, 2019 at 4:26 p.m … transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is …

Kevin Conroy

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study | 10/30/2019

… C. AA sensitivity is expected to be lower in a prospective study. “The data presented at ACG are promising,” said Kevin Conroy, chairman and CEO of Exact Sciences. “This new study demonstrates the potential to … 16368-16373. About Exact Sciences Corp. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has exclusive intellectual property protecting …

Michael McGarrity

MDxHealth Provides Q3-2019 Business Update | Globe Newswire | 11/11/2019

November 11, 2019 09:13 ET Source: MDxHealth (R) multilang-release IRVINE, CA, and HERSTAL, BELGIUM – November 11, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019. Michael McGarrity, CEO of MDxHealth, said: “During this transitional period for MDxHealth we have set a foundation that will enable us to drive growth into our …

MDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase – Company Announcement - FT.com | Financial Times | 9/27/2019

molecular diagnostics company, announces the successful pricing of its capital increase with the offering of new ordinary shares. The Company raised EUR 9.0 million (USD 9.8 million) (1) in gross proceeds by means of a private placement of 10,589,236 new shares at an issue price of EUR 0.85 per share through an accelerated bookbuilding (the “ Capital Increase “). Michael McGarrity, CEO of MDxHealth, said: “ We are pleased to have secured additional …

Thomas Schinecker

Matthew Sause | 11/8/2019

… with the Roche Group. In the Diagnostics division at Roche from 2002-14, Sause’s experience included U.S.-based sales roles in Molecular Diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In the Pharmaceuticals … to have gained a highly experienced leader in Matt,” said Thomas Schinecker, Chief Executive Officer of the Diagnostics division for the Roche Group. “He brings deep understanding of diagnostics in unique combination with many years …

Roche Diagnostics Appoints New CEO | 10/29/2019

… with the Roche Group. In the Diagnostics division at Roche from 2002-2014, Sause’s experience included U.S.-based sales roles in Molecular Diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In the Pharmaceuticals … to have gained a highly experienced leader in Matt,” said Thomas Schinecker, chief executive officer of the Diagnostics division for the Roche Group. “He brings deep understanding of diagnostics in unique combination with many years …

Steve MacMillan

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q4 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… Conference Call November 6, 2019 4:30 PM ET Company Participants Mike Watts - Vice President of Investor Relations and Corporate Communications Steve MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call … very good results in our largest businesses, Breast Health and Molecular Diagnostics, we were excited by the continued strengthening of Surgical, which posted its best growth in 10 quarters. Before we discuss the quarterly details …

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2019 | Business Wire | 11/6/2019

… Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “This growth was strong and balanced, with sales increasing in each of our divisions both domestically and outside the United States. In addition to very good results in Breast Health and Molecular Diagnostics, we are excited by the continued strengthening of our Surgical division.” Recent Highlights U.S. revenue of $656.2 million increased 6.7%, the best growth rate of the year. International …